Reblozyl (luspatercept-aamt) - BMS, Merck (MSD)
Interest of luspatercept in treatment of anemia in lower-risk of myelodysplastic syndrome anemia: a single center study of 26 patients. (PubMed, Blood Res) - Oct 8, 2026 - "Luspatercept appears to be effective in improving red blood cell production and reducing transfusion requirements in low-risk patients with MDS, with a favorable safety profile." 
Journal • Review • Anemia • Fatigue • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Oncology • SF3B1
http://www.ncbi.nlm.nih.gov/pubmed/42842186
 
A Elalaoui; C Girault; T Cluzeau
 
Oct 8, 2026
 
Prev Next